Tamarack Advisers LP trimmed its position in DocGo Inc. (NASDAQ:DCGO – Free Report) by 77.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 135,000 shares of the company’s stock after selling 475,000 shares during the quarter. DocGo accounts for 0.4% of Tamarack Advisers LP’s holdings, making the stock its 25th largest holding. Tamarack Advisers LP owned about 0.13% of DocGo worth $1,265,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in DCGO. Federated Hermes Inc. purchased a new stake in DocGo during the third quarter worth $29,000. Royal Bank of Canada lifted its stake in shares of DocGo by 226.3% during the 1st quarter. Royal Bank of Canada now owns 3,263 shares of the company’s stock worth $30,000 after purchasing an additional 2,263 shares during the last quarter. Wells Fargo & Company MN boosted its position in DocGo by 320.1% during the fourth quarter. Wells Fargo & Company MN now owns 6,192 shares of the company’s stock valued at $44,000 after purchasing an additional 4,718 shares in the last quarter. State of Wyoming purchased a new position in DocGo in the fourth quarter valued at about $50,000. Finally, Amundi bought a new position in DocGo in the fourth quarter worth about $60,000. Institutional investors own 52.14% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price target on shares of DocGo in a report on Monday, October 2nd. BTIG Research reduced their price target on DocGo from $15.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, September 19th. Needham & Company LLC reiterated a “buy” rating and set a $14.00 price objective on shares of DocGo in a report on Monday, September 18th. Northland Securities boosted their target price on DocGo from $15.00 to $16.00 in a research note on Tuesday, August 8th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $12.00 price target on shares of DocGo in a research note on Monday, September 18th.
Insider Buying and Selling
In related news, General Counsel Ely D. Tendler sold 10,000 shares of DocGo stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $5.29, for a total transaction of $52,900.00. Following the completion of the sale, the general counsel now owns 23,088 shares of the company’s stock, valued at $122,135.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 35,334 shares of company stock worth $237,854 in the last 90 days. Insiders own 13.78% of the company’s stock.
DocGo Trading Up 9.6 %
NASDAQ DCGO opened at $6.19 on Wednesday. DocGo Inc. has a 12-month low of $4.88 and a 12-month high of $10.82. The company has a fifty day simple moving average of $5.89 and a two-hundred day simple moving average of $7.93. The company has a current ratio of 2.36, a quick ratio of 2.36 and a debt-to-equity ratio of 0.01. The stock has a market cap of $642.46 million, a P/E ratio of 68.78 and a beta of 1.05.
DocGo Company Profile
DocGo Inc provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services.
- Five stocks we like better than DocGo
- What is a Bond Market Holiday? How to Invest and Trade
- 5 must-have next-gen technologies that institutions are buying
- What is Forex and How Does it Work?
- 3 intriguing late-week earnings plays for short-term traders
- Canada Bond Market Holiday: How to Invest and Trade
- Datadog is about to hit 52-week highs, and there’s more to come
Receive News & Ratings for DocGo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DocGo and related companies with MarketBeat.com's FREE daily email newsletter.